Chronic vasodilator therapy with flosequinan in <font color="blue">congestive_1</font> <font color="blue">heart_1</font> <font color="blue">failure_1</font> <font color="blue">._1</font> 
<br>
<br> This study was conducted to determine the <font color="blue">long_1</font> <font color="blue">-_1</font> <font color="blue">term_1</font> <font color="blue">effect_1</font> <font color="blue">of_1</font> <font color="blue">flosequinan_1</font> <font color="blue">,_1</font> a new orally administered arterial and venous dilator , on the clinical course of patients with <font color="blue">moderate_1</font> <font color="blue">to_1</font> <font color="blue">severe_1</font> <font color="blue">congestive_1</font> <font color="blue">heart_1</font> <font color="blue">failure_1</font> <font color="blue">._1</font> Seventeen patients on chronic digitalis and diuretic therapy were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8) in a double - blind fashion . <font color="blue">Changes_1</font> <font color="blue">in_1</font> <font color="blue">symptomatology_4</font> <font color="blue">,_4</font> <font color="blue">exercise_4</font> <font color="blue">performance_4</font> <font color="blue">,_4</font> <font color="blue">and_2</font> <font color="blue">left_4</font> <font color="blue">ventricular_4</font> <font color="blue">function_4</font> were assessed serially during the two - month treatment period . During the course of therapy , a <font color="blue">modest_1</font> <font color="blue">improvement_1</font> in the <font color="blue">symptom_4</font> <font color="blue">scores_4</font> <font color="blue">and_2</font> <font color="blue">functional_3</font> <font color="blue">classification_3</font> of the flosequinan - treated patients was observed . Flosequinan evoked a <font color="blue">significant_1</font> <font color="blue">increase_1</font> in <font color="blue">maximal_6</font> <font color="blue">exercise_6</font> <font color="blue">capacity_6</font> <font color="blue">._6</font> While long - term flosequinan administration also effected a <font color="blue">progressive_1</font> <font color="blue">increase_2</font> <font color="blue">in_1</font> <font color="blue">resting_7</font> <font color="blue">heart_7</font> <font color="blue">rate_7</font> <font color="blue">,_7</font> it <font color="blue">did_1</font> <font color="blue">not_1</font> <font color="blue">consistently_1</font> <font color="blue">improve_1</font> indices of <font color="blue">left_4</font> <font color="blue">ventricular_4</font> <font color="blue">systolic_4</font> <font color="blue">function_4</font> <font color="blue">._4</font> The addition of chronic vasodilator therapy with flosequinan to standard digitalis - diuretic regimens is capable of <font color="blue">inducing_1</font> <font color="blue">clinical_2</font> <font color="blue">improvement_2</font> in patients with moderate to severe chronic heart failure . Trials involving larger patient populations will be necessary to confirm the results of this preliminary study and to determine the extent of <font color="blue">clinical_1</font> <font color="blue">improvement_1</font> <font color="blue">,_1</font> subpopulations benefited , role in heart failure therapeutics , and so forth .